MCID: OVR078
MIFTS: 67

Ovarian Cancer, Somatic

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer, Somatic

MalaCards integrated aliases for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 54 24 13
Ovarian Cancer 12 50 25 71 29 52 41 3 14
Ovarian Carcinoma 12 50 25 13 52 14 69
Ovarian Neoplasm 12 29 69
Adenocarcinoma, Ovarian, Somatic 54 13
Epithelial Ovarian Cancer 71 69
Primary Malignant Neoplasm of Ovary 69
Ovarian Cancer, Susceptibility to 13
Malignant Neoplasm of the Ovary 25
Malignant Tumor of the Ovary 25
Malignant Neoplasm of Ovary 69
Ovarian Carcinoma, Somatic 54
Malignant Tumour of Ovary 12
Ovarian Epithelial Cancer 42
Malignant Ovarian Tumor 12
Primary Ovarian Cancer 12
Cancer of the Ovary 25
Tumor of the Ovary 12
Neoplasm of Ovary 29
Ovarian Neoplasms 42
Ovary Neoplasm 12
Oc 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant


HPO:

32
ovarian cancer, somatic:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Ovarian Cancer, Somatic

NIH Rare Diseases : 50 ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. many people with early ovarian cancer have no signs or symptoms of the condition. when present, symptoms are often nonspecific and blamed on other, more common conditions. most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as brca1 or brca2 hereditary breast and ovarian cancer syndrome, lynch syndrome and peutz-jeghers syndrome) and are inherited in an autosomal dominant manner. the best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy). last updated: 3/30/2015

MalaCards based summary : Ovarian Cancer, Somatic, also known as ovarian cancer, is related to pancreatic cancer and colorectal cancer, and has symptoms including breast carcinoma, dysgerminoma and ovarian papillary adenocarcinoma. An important gene associated with Ovarian Cancer, Somatic is OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include ovary, testes and lung, and related phenotypes are Decreased cell migration and Increased cell death HMECs cells

UniProtKB/Swiss-Prot : 71 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

MedlinePlus : 41 the ovaries are part of the female reproductive system. they produce a woman's eggs and female hormones. each ovary is about the size and shape of an almond. cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. the sooner ovarian cancer is found and treated, the better your chance for recovery. but ovarian cancer is hard to detect early. women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. then it is hard to treat. symptoms may include a heavy feeling in the pelvis pain in the lower abdomen bleeding from the vagina weight gain or loss abnormal periods unexplained back pain that gets worse gas, nausea, vomiting, or loss of appetite to diagnose ovarian cancer, doctors do one or more tests. they include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. treatment is usually surgery followed by chemotherapy. nih: national cancer institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Genetics Home Reference : 25 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

OMIM : 54
Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

Wikipedia : 72 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer, Somatic

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
id Related Disease Score Top Affiliating Genes
1 pancreatic cancer 34.1 CDH1 EGFR NME1 PIK3CA TP53
2 colorectal cancer 32.6 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
3 lung cancer 32.4 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
4 prostate cancer 32.2 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
5 endocervicitis 31.9 BRCA1 BRCA2 ERBB2 TP53
6 peritoneal mesothelioma 31.9 CDH1 CTNNB1 KRAS PIK3CA TP53
7 serous cystadenocarcinoma 31.6 AKT1 MUC16 PGR TP53 VEGFA
8 measles 31.5 EGFR ERBB2 VEGFA
9 gastrointestinal stromal tumor 31.4 AKT1 EGFR TP53 VEGFA
10 hereditary breast ovarian cancer 12.3
11 exudative vitreoretinopathy 7 12.1 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
12 breast-ovarian cancer, familial 4 12.1
13 breast-ovarian cancer, familial 3 12.1
14 childhood ovarian cancer 12.1
15 brca1 hereditary breast and ovarian cancer syndrome 12.1
16 brca2 hereditary breast and ovarian cancer syndrome 12.1
17 breast-ovarian cancer, familial, 1 12.1
18 breast-ovarian cancer, familial, 2 12.1
19 systemic lupus erythematosus with nephritis 2 12.0 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
20 trachea squamous cell carcinoma 11.9 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
21 brca1 and brca2 hereditary breast and ovarian cancer 11.8
22 lethal congenital contracture syndrome 10 11.8 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
23 adrenal cortical carcinoma 11.8 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
24 dental caries 11.8 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
25 nasal cavity disease 11.8 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS
26 bardet-biedl syndrome 11.8 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
27 gallbladder cancer 11.7 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
28 hartnup disorder 11.7 CDH1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
29 brown-vialetto-van laere syndrome 11.7 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
30 gastric cancer, somatic 11.7 CDH1 CTNNB1 EGFR ERBB2 KRAS NME1
31 nail disorder, nonsyndromic congenital, 3, 11.7 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
32 gastric fundus cancer 11.7 CDH1 CTNNB1 EGFR ERBB2 KRAS NME1
33 hereditary site-specific ovarian cancer syndrome 11.7
34 rad51c-related familial susceptibility to breast-ovarian cancer 11.7
35 rad51d-related familial susceptibility to breast-ovarian cancer 11.7
36 brca1- and brca2-associated hereditary breast and ovarian cancer 11.7
37 estrogen-receptor negative breast cancer 11.7 AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
38 nail disorder, nonsyndromic congenital, 1 11.7 BRCA1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
39 paroxysmal nocturnal hemoglobinuria 11.7 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
40 esophagus lymphoma 11.7 CDH1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
41 familiar ovarian carcinoma 11.7
42 breast granular cell tumor 11.7 BRCA1 CDH1 CTNNB1 EGFR ERBB2 NME1
43 distal monosomy 7q36 11.7 BRCA1 BRCA2 EGFR ERBB2 MUC16 PGR
44 sertoli-leydig cell tumor 11.7 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
45 brenner tumor of ovary 11.7 BRCA1 BRCA2 BRIP1 ERBB2 PALB2 PIK3CA
46 brenner tumor of the vagina 11.7 BRCA1 BRCA2 BRIP1 ERBB2 PALB2 PIK3CA
47 pancreatic somatostatinoma 11.7 AKT1 BRCA2 CDH1 CTNNB1 EGFR KRAS
48 ductal carcinoma in situ 11.7 BRCA1 BRCA2 CDH1 EGFR ERBB2 PGR
49 acute porphyria 11.7 CDH1 CTNNB1 EGFR ERBB2 KRAS NME1
50 endometriosis of uterus 11.7 CTNNB1 EGFR ERBB2 KRAS PGR TP53

Comorbidity relations with Ovarian Cancer, Somatic via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Neutropenia
Paralytic Ileus Peritoneum Cancer
Protein-Energy Malnutrition Uterine Fibroid

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to Ovarian Cancer, Somatic

Symptoms & Phenotypes for Ovarian Cancer, Somatic

Symptoms via clinical synopsis from OMIM:

54

Oncology:
breast cancer
ovarian cancer
dysgerminoma
ovarian papillary adenocarcinoma
serous ovarian cystadenocarcinoma

Lab:
frequent loss of heterozygosity at 6q24-q27


Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 breast carcinoma 32 HP:0003002
2 dysgerminoma 32 HP:0100621
3 ovarian papillary adenocarcinoma 32 HP:0006774
4 abnormality of metabolism/homeostasis 32 HP:0001939

UMLS symptoms related to Ovarian Cancer, Somatic:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.72 AKT1 CTNNB1 EGFR KRAS PIK3CA
2 Increased cell death HMECs cells GR00103-A-0 9.63 EGFR PGR PIK3CA TP53 BRCA1 CTNNB1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 AKT1 BRCA1 BRCA2 PALB2 PRKN TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 AKT1 BRCA1 BRCA2 BRIP1 PALB2 PRKN
5 Decreased viability with cisplatin GR00101-A-4 9.43 BRCA1 BRCA2 BRIP1
6 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 BRIP1

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
2 cardiovascular system MP:0005385 10.49 PIK3CA PRKN RRAS2 TP53 VEGFA AKT1
3 growth/size/body region MP:0005378 10.47 FOLR1 KRAS NME1 PALB2 PIK3CA PRKN
4 endocrine/exocrine gland MP:0005379 10.45 CTNNB1 EGFR ERBB2 FOLR1 KRAS NME1
5 embryo MP:0005380 10.43 PALB2 PGR PIK3CA TP53 VEGFA AKT1
6 homeostasis/metabolism MP:0005376 10.43 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
7 integument MP:0010771 10.41 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
8 mortality/aging MP:0010768 10.4 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
9 neoplasm MP:0002006 10.39 FOLR1 KRAS NME1 PALB2 PGR PIK3CA
10 behavior/neurological MP:0005386 10.36 AKT1 BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
11 immune system MP:0005387 10.33 VEGFA AKT1 BRCA1 BRCA2 CDH1 CTNNB1
12 nervous system MP:0003631 10.31 AKT1 BRCA1 BRCA2 BRIP1 CTNNB1 EGFR
13 digestive/alimentary MP:0005381 10.29 BRCA1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
14 limbs/digits/tail MP:0005371 10.22 BRCA1 BRCA2 CTNNB1 EGFR ERBB2 KRAS
15 muscle MP:0005369 10.22 EGFR ERBB2 KRAS PGR PIK3CA PRKN
16 craniofacial MP:0005382 10.14 CTNNB1 EGFR ERBB2 FOLR1 KRAS TP53
17 liver/biliary system MP:0005370 10.11 AKT1 BRIP1 CTNNB1 EGFR KRAS NME1
18 normal MP:0002873 10.11 BRCA1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
19 no phenotypic analysis MP:0003012 10.1 CDH1 CTNNB1 EGFR KRAS OPCML PGR
20 reproductive system MP:0005389 10.07 KRAS PGR PIK3CA TP53 VEGFA AKT1
21 respiratory system MP:0005388 9.81 EGFR ERBB2 KRAS PRKN TP53 VEGFA
22 skeleton MP:0005390 9.73 EGFR ERBB2 KRAS PGR PIK3CA PRKN
23 pigmentation MP:0001186 9.72 EGFR KRAS TP53 BRCA1 CTNNB1
24 vision/eye MP:0005391 9.23 CTNNB1 EGFR FOLR1 KRAS PIK3CA RRAS2

Drugs & Therapeutics for Ovarian Cancer, Somatic

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
CEA-Scan 17 Immunomedics April 1996
2
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 17 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 17 46 GEFITINIB AstraZeneca May 2003
6
Lynparza 17 46 OLAPARIB AstraZeneca December 2014

Drugs for Ovarian Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
3
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
4 Talazoparib Investigational Phase 2 1207456-01-6
5
Veliparib Investigational Phase 2 912444-00-9 11960529
6 Kava Nutraceutical 9000-38-8

Interventional clinical trials:

(show all 18)

id Name Status NCT ID Phase Drugs
1 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4 Olaparib
2 Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations Withdrawn NCT02392676 Phase 3 OLAPARIB;PLACEBO
3 Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Recruiting NCT02983799 Phase 2 OLAPARIB
4 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Active, not recruiting NCT01482715 Phase 1, Phase 2 Rucaparib
5 Phase II Study of BMN 673 Active, not recruiting NCT02286687 Phase 2 Talazoparib Tosylate
6 Response to PARP Inhibitor Predicted by the RAD51 Assay Not yet recruiting NCT03044795 Phase 2 Veliparib
7 Selumetinib and Olaparib in Solid Tumors Recruiting NCT03162627 Phase 1 Selumetinib;Olaparib
8 BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer Completed NCT02963688
9 Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs. Completed NCT02323568
10 FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study Recruiting NCT02984423
11 Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region Recruiting NCT03082976
12 Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity Recruiting NCT02518256
13 Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation Recruiting NCT02664389
14 Clinical Significance of Germline BRCA Mutations Recruiting NCT00579488
15 EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies Recruiting NCT02701907
16 A Study of Long-Term Responders on Olaparib Recruiting NCT02489058
17 Prevalence of BRCA in Patients With Ovarian Cancer Active, not recruiting NCT02222883
18 Inherited Susceptible Genes Among Epithelial Ovarian Cancer Not yet recruiting NCT03015376

Search NIH Clinical Center for Ovarian Cancer, Somatic

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer, Somatic

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Neoplasm of Ovary 29
2 Ovarian Cancer 29
3 Ovarian Neoplasm 29
4 Ovarian Cancer, Somatic 24 AKT1 PIK3CA ERBB2

Anatomical Context for Ovarian Cancer, Somatic

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

39
Ovary, Testes, Lung, Liver, Lymph Node, Cervix

Publications for Ovarian Cancer, Somatic

Variations for Ovarian Cancer, Somatic

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

71
id Symbol AA change Variation ID SNP ID
1 BRCA1 p.Cys61Gly VAR_007757 rs28897672
2 BRCA1 p.Cys1697Arg VAR_020702 rs80356993
3 BRCA1 p.Arg1699Trp VAR_075666 rs55770810
4 CTNNB1 p.Ser37Cys VAR_017625 rs121913403
5 CTNNB1 p.Thr41Ile VAR_017630 rs121913413
6 OPCML p.Pro95Arg VAR_055421 rs137852691
7 PIK3CA p.His1047Arg VAR_026192 rs121913279

ClinVar genetic disease variations for Ovarian Cancer, Somatic:

6 (show top 50) (show all 66)
id Gene Variation Type Significance SNP ID Assembly Location
1 PRKN PARK2, DEL deletion Pathogenic
2 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
3 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
4 OPCML NM_001012393.2(OPCML): c.263C> G (p.Pro88Arg) single nucleotide variant Pathogenic rs137852691 GRCh37 Chromosome 11, 132527098: 132527098
5 RRAS2 NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu) single nucleotide variant Pathogenic rs113954997 GRCh37 Chromosome 11, 14316390: 14316390
6 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
7 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
8 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
9 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
10 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
11 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
12 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
15 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
16 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
17 ERBB2 NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 GRCh37 Chromosome 17, 37881378: 37881378
18 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
19 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
20 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
21 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
22 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
23 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
24 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
25 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
26 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
27 BRCA1 NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter) single nucleotide variant Pathogenic rs80356898 GRCh37 Chromosome 17, 41245861: 41245861
28 BRCA2 NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter) single nucleotide variant Pathogenic rs41293497 GRCh37 Chromosome 13, 32914174: 32914174
29 KRAS NM_033360.3(KRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
30 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
31 BRCA2 NM_000059.3(BRCA2): c.7806-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs81002836 GRCh37 Chromosome 13, 32936658: 32936658
32 BRCA1 NM_007294.3(BRCA1): c.3375_3376delTC (p.Pro1126Ilefs) deletion Pathogenic rs80357828 GRCh37 Chromosome 17, 41244172: 41244173
33 BRCA1 NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp) single nucleotide variant Pathogenic rs55770810 GRCh37 Chromosome 17, 41215948: 41215948
34 PALB2 NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs) deletion Pathogenic rs515726060 GRCh38 Chromosome 16, 23635493: 23635496
35 BRIP1 NM_032043.2(BRIP1): c.2038_2039dupTT (p.Leu680Phefs) duplication Pathogenic/Likely pathogenic rs587778134 GRCh37 Chromosome 17, 59853820: 59853821
36 BRIP1 NM_032043.2(BRIP1): c.1240C> T (p.Gln414Ter) single nucleotide variant Pathogenic/Likely pathogenic rs368796923 GRCh37 Chromosome 17, 59876561: 59876561
37 BRIP1 NM_032043.2(BRIP1): c.1853_1854insG (p.Pro619Thrfs) insertion Pathogenic/Likely pathogenic rs587781985 GRCh37 Chromosome 17, 59857703: 59857704
38 BRIP1 NM_032043.2(BRIP1): c.2765T> G (p.Leu922Ter) single nucleotide variant Pathogenic rs587782410 GRCh37 Chromosome 17, 59763337: 59763337
39 NC_012920.1: m.14743A> G single nucleotide variant Likely pathogenic rs527236161 GRCh37 Chromosome MT, 14743: 14743
40 MT-CYB NC_012920.1: m.14753C> T single nucleotide variant Likely pathogenic rs527236162 GRCh38 Chromosome MT, 14753: 14753
41 MT-CYB NC_012920.1: m.14784T> C single nucleotide variant Likely pathogenic rs527236163 GRCh37 Chromosome MT, 14784: 14784
42 MT-CYB NC_012920.1: m.15058C> T single nucleotide variant Likely pathogenic rs527236171 GRCh37 Chromosome MT, 15058: 15058
43 MT-CYB NC_012920.1: m.15098A> G single nucleotide variant Likely pathogenic rs527236172 GRCh37 Chromosome MT, 15098: 15098
44 MT-CYB NC_012920.1: m.15314G> A single nucleotide variant Likely pathogenic rs527236176 GRCh37 Chromosome MT, 15314: 15314
45 MT-CYB NC_012920.1: m.15328A> G single nucleotide variant Likely pathogenic rs527236178 GRCh37 Chromosome MT, 15328: 15328
46 MT-CYB NC_012920.1: m.15334C> T single nucleotide variant Likely pathogenic rs527236179 GRCh37 Chromosome MT, 15334: 15334
47 MT-CYB NC_012920.1: m.15363A> G single nucleotide variant Likely pathogenic rs527236182 GRCh37 Chromosome MT, 15363: 15363
48 MT-CYB NC_012920.1: m.15453T> C single nucleotide variant Likely pathogenic rs527236184 GRCh37 Chromosome MT, 15453: 15453
49 MT-CYB NC_012920.1: m.15459C> T single nucleotide variant Likely pathogenic rs527236186 GRCh37 Chromosome MT, 15459: 15459
50 MT-CYB NC_012920.1: m.15884G> A single nucleotide variant Likely pathogenic rs527236195 GRCh37 Chromosome MT, 15884: 15884

Cosmic variations for Ovarian Cancer, Somatic:

9 (show all 32)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 16
2 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 16
3 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 16
4 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 16
5 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 16
6 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 16
7 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 16
8 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 16
9 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 16
10 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 16
11 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 16
12 COSM520 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 16
13 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 16
14 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 16
15 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 16
16 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 16
17 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 16
18 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 16
19 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 16
20 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 16
21 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 16
22 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 16
23 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 16
24 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 16
25 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 16
26 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 16
27 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 16
28 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 16
29 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 16
30 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 16
31 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 16
32 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 16

Copy number variations for Ovarian Cancer, Somatic from CNVD:

7 (show top 50) (show all 8010)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13413 1 1 23549970 Deletion AADACL3 Ovarian cancer
2 13414 1 1 23549970 Deletion AADACL4 Ovarian cancer
3 13415 1 1 23549970 Deletion ACAP3 Ovarian cancer
4 13416 1 1 23549970 Deletion ACOT7 Ovarian cancer
5 13417 1 1 23549970 Deletion ACTL8 Ovarian cancer
6 13418 1 1 23549970 Deletion ACTRT2 Ovarian cancer
7 13419 1 1 23549970 Deletion AGMAT Ovarian cancer
8 13420 1 1 23549970 Deletion AGRN Ovarian cancer
9 13421 1 1 23549970 Deletion AGTRAP Ovarian cancer
10 13422 1 1 23549970 Deletion AJAP1 Ovarian cancer
11 13423 1 1 23549970 Deletion AKR7A2 Ovarian cancer
12 13424 1 1 23549970 Deletion AKR7A3 Ovarian cancer
13 13425 1 1 23549970 Deletion AKR7L Ovarian cancer
14 13426 1 1 23549970 Deletion ALDH4A1 Ovarian cancer
15 13427 1 1 23549970 Deletion ALPL Ovarian cancer
16 13428 1 1 23549970 Deletion ANGPTL7 Ovarian cancer
17 13429 1 1 23549970 Deletion APITD1 Ovarian cancer
18 13430 1 1 23549970 Deletion ARHGEF10L Ovarian cancer
19 13431 1 1 23549970 Deletion ARHGEF16 Ovarian cancer
20 13432 1 1 23549970 Deletion ARHGEF19 Ovarian cancer
21 13433 1 1 23549970 Deletion ATAD3A Ovarian cancer
22 13434 1 1 23549970 Deletion ATAD3B Ovarian cancer
23 13435 1 1 23549970 Deletion ATAD3C Ovarian cancer
24 13436 1 1 23549970 Deletion ATP13A2 Ovarian cancer
25 13437 1 1 23549970 Deletion AURKAIP1 Ovarian cancer
26 13438 1 1 23549970 Deletion B3GALT6 Ovarian cancer
27 13439 1 1 23549970 Deletion C1QA Ovarian cancer
28 13440 1 1 23549970 Deletion C1QB Ovarian cancer
29 13441 1 1 23549970 Deletion C1QC Ovarian cancer
30 13442 1 1 23549970 Deletion C1orf126 Ovarian cancer
31 13443 1 1 23549970 Deletion C1orf127 Ovarian cancer
32 13444 1 1 23549970 Deletion C1orf144 Ovarian cancer
33 13445 1 1 23549970 Deletion C1orf151 Ovarian cancer
34 13446 1 1 23549970 Deletion C1orf158 Ovarian cancer
35 13447 1 1 23549970 Deletion C1orf159 Ovarian cancer
36 13448 1 1 23549970 Deletion C1orf170 Ovarian cancer
37 13449 1 1 23549970 Deletion C1orf174 Ovarian cancer
38 13450 1 1 23549970 Deletion C1orf187 Ovarian cancer
39 13451 1 1 23549970 Deletion C1orf200 Ovarian cancer
40 13452 1 1 23549970 Deletion C1orf64 Ovarian cancer
41 13453 1 1 23549970 Deletion C1orf70 Ovarian cancer
42 13454 1 1 23549970 Deletion C1orf86 Ovarian cancer
43 13455 1 1 23549970 Deletion C1orf89 Ovarian cancer
44 13456 1 1 23549970 Deletion C1orf93 Ovarian cancer
45 13457 1 1 23549970 Deletion CA6 Ovarian cancer
46 13458 1 1 23549970 Deletion CALML6 Ovarian cancer
47 13459 1 1 23549970 Deletion CAMK2N1 Ovarian cancer
48 13460 1 1 23549970 Deletion CAMTA1 Ovarian cancer
49 13461 1 1 23549970 Deletion CAPZB Ovarian cancer
50 13462 1 1 23549970 Deletion CASP9 Ovarian cancer

Expression for Ovarian Cancer, Somatic

Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for Ovarian Cancer, Somatic

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50) (show all 102)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 AKT1 BRCA1 CDH1 EGFR ERBB2 KRAS
2
Show member pathways
13.55 AKT1 CDH1 EGFR ERBB2 KRAS PIK3CA
3
Show member pathways
13.39 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
4
Show member pathways
13.38 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
5
Show member pathways
13.09 AKT1 CDH1 CTNNB1 KRAS RRAS2 TP53
6
Show member pathways
13.02 AKT1 BRCA1 BRCA2 BRIP1 KRAS RRAS2
7
Show member pathways
13 AKT1 EGFR ERBB2 KRAS PIK3CA VEGFA
8
Show member pathways
12.97 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
9
Show member pathways
12.96 AKT1 EGFR ERBB2 KRAS PIK3CA RRAS2
10
Show member pathways
12.88 AKT1 CDH1 CTNNB1 ERBB2 KRAS PIK3CA
11
Show member pathways
12.87 AKT1 CTNNB1 EGFR KRAS PIK3CA VEGFA
12
Show member pathways
12.83 AKT1 EGFR ERBB2 KRAS PIK3CA TP53
13 12.8 AKT1 EGFR KRAS RRAS2 TP53
14
Show member pathways
12.78 AKT1 CDH1 CTNNB1 EGFR KRAS PIK3CA
15
Show member pathways
12.76 AKT1 EGFR KRAS RRAS2 TP53
16 12.76 AKT1 BRCA1 CTNNB1 EGFR KRAS PIK3CA
17
Show member pathways
12.68 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
18
Show member pathways
12.61 AKT1 EGFR ERBB2 KRAS PIK3CA TP53
19 12.6 BRCA1 EGFR ERBB2 KRAS PIK3CA TP53
20 12.55 AKT1 BRCA2 CDH1 CTNNB1 EGFR ERBB2
21 12.53 AKT1 CTNNB1 KRAS PIK3CA RRAS2 TP53
22
Show member pathways
12.52 AKT1 CTNNB1 EGFR KRAS RRAS2
23
Show member pathways
12.51 AKT1 EGFR KRAS PIK3CA RRAS2
24
Show member pathways
12.51 AKT1 BRCA1 CTNNB1 KRAS PIK3CA VEGFA
25
Show member pathways
12.51 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
26
Show member pathways
12.47 AKT1 EGFR KRAS RRAS2 VEGFA
27
Show member pathways
12.45 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
28
Show member pathways
12.42 AKT1 KRAS PGR PIK3CA
29
Show member pathways
12.4 AKT1 EGFR ERBB2 PIK3CA
30
Show member pathways
12.4 AKT1 EGFR ERBB2 KRAS PIK3CA
31
Show member pathways
12.4 AKT1 EGFR ERBB2 KRAS PIK3CA TP53
32
Show member pathways
12.37 BRCA1 BRCA2 BRIP1 PALB2
33
Show member pathways
12.36 AKT1 EGFR ERBB2 KRAS PIK3CA TP53
34
Show member pathways
12.32 AKT1 EGFR KRAS VEGFA
35
Show member pathways
12.31 AKT1 KRAS TP53 VEGFA
36
Show member pathways
12.31 AKT1 CDH1 CTNNB1 EGFR ERBB2 KRAS
37
Show member pathways
12.29 AKT1 KRAS PIK3CA RRAS2
38 12.28 AKT1 EGFR ERBB2 KRAS
39
Show member pathways
12.27 AKT1 KRAS PIK3CA TP53
40
Show member pathways
12.26 AKT1 EGFR ERBB2 KRAS PIK3CA
41
Show member pathways
12.24 AKT1 KRAS RRAS2 TP53
42
Show member pathways
12.24 BRCA1 BRCA2 BRIP1 PALB2
43
Show member pathways
12.24 AKT1 KRAS PIK3CA TP53
44
Show member pathways
12.23 AKT1 CTNNB1 EGFR ERBB2 PIK3CA
45 12.22 AKT1 CDH1 CTNNB1 EGFR KRAS TP53
46 12.2 AKT1 CTNNB1 PIK3CA TP53 VEGFA
47 12.19 AKT1 CTNNB1 KRAS PIK3CA
48
Show member pathways
12.18 AKT1 EGFR KRAS PIK3CA
49 12.18 AKT1 CDH1 KRAS RRAS2
50 12.17 AKT1 KRAS PRKN TP53

GO Terms for Ovarian Cancer, Somatic

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1
2 perinuclear region of cytoplasm GO:0048471 9.63 CDH1 CTNNB1 EGFR ERBB2 NME1 PRKN
3 basolateral plasma membrane GO:0016323 9.56 CTNNB1 EGFR ERBB2 FOLR1
4 catenin complex GO:0016342 9.37 CDH1 CTNNB1
5 flotillin complex GO:0016600 9.32 CDH1 CTNNB1
6 protein complex GO:0043234 9.1 AKT1 BRCA1 BRCA2 CTNNB1 PRKN TP53

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 regulation of signal transduction by p53 class mediator GO:1901796 9.92 AKT1 BRCA1 BRIP1 TP53
2 regulation of apoptotic process GO:0042981 9.91 BRCA1 CTNNB1 NME1 TP53
3 cellular response to hypoxia GO:0071456 9.89 AKT1 BRIP1 TP53 VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.89 AKT1 EGFR ERBB2 KRAS VEGFA
5 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.86 AKT1 EGFR ERBB2 PIK3CA
6 positive regulation of cell growth GO:0030307 9.85 AKT1 EGFR ERBB2
7 double-strand break repair via homologous recombination GO:0000724 9.84 BRCA1 BRCA2 PALB2
8 Ras protein signal transduction GO:0007265 9.83 KRAS RRAS2 TP53
9 cellular response to drug GO:0035690 9.83 EGFR NME1 TP53
10 double-strand break repair GO:0006302 9.83 BRCA1 BRCA2 BRIP1
11 negative regulation of neuron death GO:1901215 9.81 AKT1 CTNNB1 PRKN
12 positive regulation of epithelial cell proliferation GO:0050679 9.81 EGFR ERBB2 NME1 VEGFA
13 cellular response to epidermal growth factor stimulus GO:0071364 9.8 AKT1 EGFR ERBB2
14 phosphatidylinositol-mediated signaling GO:0048015 9.8 AKT1 EGFR ERBB2 PIK3CA TP53
15 positive regulation of gene expression GO:0010628 9.8 BRCA1 CTNNB1 ERBB2 KRAS PRKN TP53
16 positive regulation of MAP kinase activity GO:0043406 9.78 EGFR ERBB2 KRAS VEGFA
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.74 AKT1 PIK3CA VEGFA
18 cellular response to growth factor stimulus GO:0071363 9.73 AKT1 CTNNB1 EGFR ERBB2
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.7 BRCA1 BRCA2 TP53
20 anoikis GO:0043276 9.67 AKT1 PIK3CA
21 ERBB2 signaling pathway GO:0038128 9.67 EGFR ERBB2 KRAS PIK3CA
22 protein K6-linked ubiquitination GO:0085020 9.65 BRCA1 PRKN
23 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.64 AKT1 EGFR
24 chordate embryonic development GO:0043009 9.63 BRCA1 BRCA2
25 epidermal growth factor receptor signaling pathway GO:0007173 9.63 EGFR KRAS PIK3CA
26 negative regulation of gene expression GO:0010629 9.63 AKT1 BRIP1 CTNNB1 NME1 PGR PRKN
27 DNA synthesis involved in DNA repair GO:0000731 9.62 BRCA1 BRCA2 BRIP1 PALB2
28 response to UV-A GO:0070141 9.61 AKT1 EGFR
29 phosphatidylinositol 3-kinase signaling GO:0014065 9.6 AKT1 ERBB2
30 cellular response to indole-3-methanol GO:0071681 9.13 BRCA1 CDH1 CTNNB1
31 strand displacement GO:0000732 8.92 BRCA1 BRCA2 BRIP1 PALB2
32 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.18 AKT1 BRCA1 CTNNB1 EGFR PGR PRKN
33 regulation of transcription from RNA polymerase II promoter GO:0006357 10.09 BRCA1 BRIP1 CTNNB1 EGFR ERBB2 VEGFA
34 positive regulation of transcription, DNA-templated GO:0045893 10.08 AKT1 BRCA1 BRCA2 CDH1 CTNNB1 EGFR
35 cellular response to DNA damage stimulus GO:0006974 10.06 AKT1 BRCA1 BRCA2 BRIP1 PALB2 TP53
36 cell proliferation GO:0008283 10.02 AKT1 BRCA2 CTNNB1 EGFR ERBB2 TP53

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.8 AKT1 BRIP1 EGFR ERBB2 KRAS
2 identical protein binding GO:0042802 9.8 AKT1 EGFR ERBB2 NME1 PRKN TP53
3 protein kinase binding GO:0019901 9.63 AKT1 CTNNB1 EGFR NME1 PRKN TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGFR ERBB2 PIK3CA
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR ERBB2
6 nitric-oxide synthase regulator activity GO:0030235 9.37 AKT1 EGFR
7 protein phosphatase binding GO:0019903 9.26 CTNNB1 EGFR ERBB2 TP53
8 enzyme binding GO:0019899 9.17 AKT1 BRCA1 CTNNB1 EGFR PGR PRKN
9 protein binding GO:0005515 10.28 AKT1 BRCA1 BRCA2 BRIP1 CDH1 CTNNB1

Sources for Ovarian Cancer, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....